清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Repurposing the β3-Adrenergic Receptor Agonist Mirabegron in Patients With Structural Cardiac Disease

医学 心力衰竭 心脏病学 内科学 米拉贝格伦 安慰剂 左心室肥大 肌肉肥大 舒张期 心房颤动 心室重构 病理 血压 替代医学 膀胱过度活动
作者
Jean‐Luc Balligand,Dulce Brito,Oana Brosteanu,Barbara Casadei,Christophe Depoix,Frank Edelmann,Vanessa M. Ferreira,Gerasimos Filippatos,Bernhard Gerber,Damien Gruson,Dirk Hasenclever,Kristian Hellenkamp,Ignatios Ikonomidis,Bartosz Krakowiak,Renaud Lhommel,Masliza Mahmod,Stefan Neubauer,Alexandre Persu,Stefan K. Piechnik,Burkert Pieske,Elisabeth Pieske‐Kraigher,Fausto J. Pinto,Piotr Ponikowski,Michele Senni,Jean Noël Trochu,Nancy Van Overstraeten,Rolf Wachter,Anne‐Catherine Pouleur
出处
期刊:JAMA Cardiology [American Medical Association]
卷期号:8 (11): 1031-1031 被引量:1
标识
DOI:10.1001/jamacardio.2023.3003
摘要

Left ventricular (LV) hypertrophy contributes to the onset and progression of heart failure (HF), particularly for patients with pre-HF (stage B) for whom no treatment has yet proven effective to prevent transition to overt HF (stage C). The β3-adrenergic receptors (β3ARs) may represent a new target, as their activation attenuates LV remodeling.To determine whether activation of β3ARs by repurposing a β3AR agonist, mirabegron, is safe and effective in preventing progression of LV hypertrophy and diastolic dysfunction among patients with pre- or mild HF.The Beta3-LVH prospective, triple-blind, placebo-controlled phase 2b randomized clinical trial enrolled patients between September 12, 2016, and February 26, 2021, with a follow-up of 12 months. The trial was conducted at 10 academic hospitals in 8 countries across Europe (Germany, Poland, France, Belgium, Italy, Portugal, Greece, and the UK). Patients aged 18 years or older with or without HF symptoms (maximum New York Heart Association class II) were screened for the presence of LV hypertrophy (increased LV mass index [LVMI] of ≥95 g/m2 for women or ≥115 g/m2 for men) or maximum wall thickness of 13 mm or greater using echocardiography. Data analysis was performed in August 2022.Participants were randomly assigned (1:1) to mirabegron (50 mg/d) or placebo, stratified by the presence of atrial fibrillation and/or type 2 diabetes, for 12 months.The primary end points were LVMI determined using cardiac magnetic resonance imaging and LV diastolic function (early diastolic tissue Doppler velocity [E/e'] ratio assessed using Doppler echocardiography) at 12 months. Patients with at least 1 valid measurement of either primary end point were included in the primary analysis. Safety was assessed for all patients who received at least 1 dose of study medication.Of the 380 patients screened, 296 were enrolled in the trial. There were 147 patients randomized to mirabegron (116 men [79%]; mean [SD] age, 64.0 [10.2] years) and 149 to placebo (112 men [75%]; mean [SD] age, 62.2 [10.9] years). All patients were included in the primary intention-to-treat analysis. At 12 months, the baseline and covariate-adjusted differences between groups included a 1.3-g/m2 increase in LVMI (95% CI, -0.15 to 2.74; P = .08) and a -0.15 decrease in E/e' (95% CI, -0.69 to 0.4; P = .60). A total of 213 adverse events (AEs) occurred in 82 mirabegron-treated patients (including 31 serious AEs in 19 patients) and 215 AEs occurred in 88 placebo-treated patients (including 30 serious AEs in 22 patients). No deaths occurred during the trial.In this study, mirabegron therapy had a neutral effect on LV mass or diastolic function over 12 months among patients who had structural heart disease with no or mild HF symptoms.ClinicalTrials.gov Identifier: NCT02599480.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
physicalpicture完成签到,获得积分10
刚刚
广州小肥羊完成签到 ,获得积分10
27秒前
32秒前
高高的玉兰完成签到,获得积分10
35秒前
体贴的惜文完成签到,获得积分10
36秒前
43秒前
KalEl发布了新的文献求助10
43秒前
49秒前
irisxiong完成签到,获得积分10
50秒前
笔墨纸砚完成签到 ,获得积分10
54秒前
务实的海豚完成签到,获得积分10
55秒前
共享精神的应助被兰兰不懒采纳,获得10
1分钟前
vbnn完成签到 ,获得积分10
1分钟前
天很蓝完成签到,获得积分10
1分钟前
饱满飞绿完成签到,获得积分10
1分钟前
子凡完成签到 ,获得积分10
1分钟前
自由的冷玉完成签到,获得积分10
1分钟前
风息完成签到,获得积分10
1分钟前
1分钟前
会飞的鹦鹉完成签到,获得积分10
1分钟前
兰兰不懒发布了新的文献求助10
1分钟前
1分钟前
1分钟前
科研通AI65的应助被科研通管家采纳,获得10
1分钟前
1分钟前
Maestro_S的应助被科研通管家采纳,获得10
1分钟前
SAY完成签到 ,获得积分10
1分钟前
fantasy的应助被shine采纳,获得10
2分钟前
激动的似狮完成签到,获得积分10
2分钟前
2分钟前
KalEl发布了新的文献求助10
2分钟前
chemlink完成签到 ,获得积分10
2分钟前
含蓄的新柔完成签到,获得积分10
2分钟前
NN的应助被Jamal采纳,获得10
2分钟前
什么也难不倒我完成签到 ,获得积分10
2分钟前
余香的应助被itsnotover采纳,获得10
2分钟前
满意野狼完成签到,获得积分10
2分钟前
3分钟前
KalEl发布了新的文献求助10
3分钟前
耍酷的手套完成签到,获得积分10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190226
求助须知:如何正确求助?哪些是违规求助? 9577355
关于积分的说明 21852358
捐赠科研通 7788746
什么是DOI,文献DOI怎么找? 3436310
关于科研通互助平台的介绍 2560106
邀请新用户注册赠送积分活动 2482911